Comments on: Trends Update — Personalized Medicine: No Medicare Funding for Warfarin Testing, For Now http://crossborderbiotech.ca/2009/05/05/trends-update-personalized-medicine-no-medicare-funding-for-warfarin-testing-for-now/ Biotechnology, Health and Business in Canada, the United States and Worldwide Mon, 02 Apr 2012 12:31:04 +0000 hourly 1 http://wordpress.com/ By: Biotech Trends Update: Costs Savings from Personalized Medicine Sought by PBMs, Employers, Pharma Face Legal and Privacy Hurdles « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/05/05/trends-update-personalized-medicine-no-medicare-funding-for-warfarin-testing-for-now/comment-page-1/#comment-1352 Thu, 04 Feb 2010 18:22:59 +0000 http://crossborderbiotech.ca/?p=1800#comment-1352 [...] a neutral funding source for comparative effectiveness and personalized medicine research (despite also being a payor). This is a problem much bigger than just personalized medicine, but until trust is restored, [...]

]]> By: Trends Update — Personalized Medicine: DxS’ Latest Companion Diagnostics Deal « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/05/05/trends-update-personalized-medicine-no-medicare-funding-for-warfarin-testing-for-now/comment-page-1/#comment-460 Sun, 31 May 2009 17:32:19 +0000 http://crossborderbiotech.ca/?p=1800#comment-460 [...] As personalized medicine inches toward becoming the standard of care for cancer, the question of who pays for the genotyping becomes more important.  A deal announced Friday between DxS, a molecular diagnostics company, [...]

]]>